First-line treatment with HDACis plus tislelizumab combined with chemotherapy in advanced NSCLC: a single-arm phase II study. Wang L, Gao M, Wang T, Cui P, et al. Oncologist 2025;30:oyaf155.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wang L, Gao M, Wang T, Cui P, et al. First-line treatment with HDACis plus tislelizumab combined with chemotherapy in advanced NSCLC: a single-arm phase II study. Oncologist 2025;30:oyaf155.
PMID: 40631772